Global Blood Therapeutics (NASDAQ:GBT) has been assigned a $73.00 target price by research analysts at HC Wainwright in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 35.81% from the stock’s current price.
A number of other research firms have also recently commented on GBT. Oppenheimer set a $53.00 target price on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday, November 13th. ValuEngine cut Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Wedbush restated an “outperform” rating and issued a $73.00 target price on shares of Global Blood Therapeutics in a research note on Monday, December 4th. Zacks Investment Research upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Cantor Fitzgerald set a $61.00 target price on Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday, December 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $69.00.
Shares of Global Blood Therapeutics (NASDAQ:GBT) opened at $53.75 on Monday. The firm has a market capitalization of $2,390.00 and a P/E ratio of -19.55. Global Blood Therapeutics has a 1 year low of $24.02 and a 1 year high of $68.05.
Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.22). equities analysts expect that Global Blood Therapeutics will post -3.61 EPS for the current year.
In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction on Monday, December 18th. The stock was sold at an average price of $36.55, for a total transaction of $109,650.00. Following the completion of the transaction, the insider now owns 135,255 shares in the company, valued at $4,943,570.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Peter Radovich sold 812 shares of Global Blood Therapeutics stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $57.30, for a total value of $46,527.60. Following the transaction, the insider now owns 6,221 shares of the company’s stock, valued at approximately $356,463.30. The disclosure for this sale can be found here. Insiders have sold 54,911 shares of company stock valued at $3,059,552 in the last quarter. 5.30% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new position in Global Blood Therapeutics during the third quarter valued at $200,000. Trexquant Investment LP purchased a new position in Global Blood Therapeutics during the third quarter valued at $202,000. Xact Kapitalforvaltning AB purchased a new position in Global Blood Therapeutics during the fourth quarter valued at $202,000. Dynamic Technology Lab Private Ltd purchased a new position in Global Blood Therapeutics during the third quarter valued at $205,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in Global Blood Therapeutics during the third quarter valued at $230,000. Institutional investors and hedge funds own 92.06% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://ledgergazette.com/2018/03/14/global-blood-therapeutics-gbt-pt-set-at-73-00-by-hc-wainwright.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.